Limitations:
This is a single centre experience and in spite of the collation of data
over seven years, we could collect information from 32 patients. Large
collaborative data sets would be necessary to throw light on this issue.
The implications of various patterns of metastases on survival would
have provided interesting insights but we were constrained by the fact
that even with a long period of follow up, only five events were
documented.
References
1. Ullmann TM, Gray KD, Moore MD,
Zarnegar R, Fahey Iii TJ. Current controversies and future directions in
the diagnosis and management of differentiated thyroid cancers.Gland Surgery. 2018;7(5):473-486.
2. Schmidbauer B, Menhart K, Hellwig
D, Grosse J. Differentiated Thyroid Cancer—Treatment: State of the
Art. IJMS. 2017;18(6):1292.
3. McLeod DSA. Current Concepts and
Future Directions in Differentiated Thyroid Cancer. Clin Biochem
Rev. 2010;31(1):9-19.
4. Li F, Chen G, Sheng C, et al.
BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.Endocrine-Related Cancer. 2015;22(2):159-168.
5. Siegel R, Ma J, Zou Z, Jemal A.
Cancer statistics, 2014. CA: A Cancer Journal for Clinicians.2014;64(1):9-29.
6. Landa I, Ibrahimpasic T, Boucai L,
et al. Genomic and transcriptomic hallmarks of poorly differentiated and
anaplastic thyroid cancers. Journal of Clinical Investigation.2016;126(3):1052-1066.
7. Elshafie OT, Hussein S, Al-Hamdani
A, Bererhi H, Woodhouse NJY. Multiple Bone Metastases in a Patient with
Differentiated Thyroid Cancer (DTC). Sultan Qaboos Univ Med J.2010;10(1):101-105.
8. Wexler JA. Approach to the Thyroid
Cancer Patient with Bone Metastases. The Journal of Clinical
Endocrinology & Metabolism. 2011;96(8):2296-2307.
9. Lin J-D, Kuo S-F, Huang B-Y, Lin
S-F, Chen S-T. The efficacy of radioactive iodine for the treatment of
well-differentiated thyroid cancer with distant metastasis. Nucl
Med Commun. 2018;39(12):1091-1096.
10. Singh Ospina N, Castro MR.
Treatment of Recurrent/Metastatic Thyroid Cancer with Radioactive
Iodine. In: Roman SA, Sosa JA, SolĂłrzano CC, eds. Management of
Thyroid Nodules and Differentiated Thyroid Cancer: A Practical Guide.Cham: Springer International Publishing; 2017:315-329.
11. Kato S, Murakami H, Demura S, et
al. The impact of complete surgical resection of spinal metastases on
the survival of patients with thyroid cancer. Cancer Med.2016;5(9):2343-2349.
12. Kushchayeva YS, Kushchayev SV,
Wexler JA, et al. Current Treatment Modalities for Spinal Metastases
Secondary to Thyroid Carcinoma. Thyroid. 2014;24(10):1443-1455.
13. Durante C, Haddy N, Baudin E, et
al. Long-Term Outcome of 444 Patients with Distant Metastases from
Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of
Radioiodine Therapy. The Journal of Clinical Endocrinology &
Metabolism. 2006;91(8):2892-2899.
14. Sherman SI. Early clinical
studies of novel therapies for thyroid cancers. Endocrinol Metab
Clin North Am. 2008;37(2):511-524, xi.
15. Lee N, Tuttle M. The role of
external beam radiotherapy in the treatment of papillary thyroid cancer.Endocrine-Related Cancer. 2006:971-977.
16. Kiess AP, Agrawal N, Brierley JD,
et al. External-beam radiotherapy for differentiated thyroid cancer
locoregional control: A statement of the American Head and Neck Society.Head Neck. 2016;38(4):493-498.
17. Porterfield JR, Cassivi SD, Wigle
DA, et al. Thoracic metastasectomy for thyroid malignancies.European Journal of Cardio-Thoracic Surgery. 2009;36(1):155-158.
18. Pitoia F, Bueno F, Cross G.
Long-Term Survival and Low Effective Cumulative Radioiodine Doses to
Achieve Remission in Patients With 131Iodine-Avid Lung Metastasis From
Differentiated Thyroid Cancer. Clinical Nuclear Medicine.2014;39(9):784-790.
19. Ceccarelli C, Canale D, Vitti P.
Radioactive iodine (131I) effects on male fertility. Current
Opinion in Urology. 2008;18(6):598-601.
20. Turaka A, Li T, Yu JQ, et al.
Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer.8.
21. Yarnold JR. 8 Gy single fraction
radiotherapy for the treatment of metastatic skeletal pain: randomised
comparison with a multifraction schedule over 12 months of patient
follow-upOn behalf of the Bone Pain Trial Working Party.Radiotherapy and Oncology. 1999;52(2):111-121.